





CP, carboplatin and paclitaxel



CPB, carboplatin, paclitaxel, and bevacizumab





**Figure 5S.**

REMARK diagram detailing patient cohorts with evaluable baseline cfDNA used in the survival analysis for the **A**, squamous and **B**, non-squamous populations. **C**, Whole-genome CNV landscape of 12 baseline cfDNA samples from non-squamous NSCLC patients with tumor fraction  $\geq$  10%. Top track shows CNV regions of significantly high frequency (q-value  $<$  0.05%). Bottom tracks show the CNV pattern of each sample. Heatmap density represents CNV log<sub>2</sub> ratios between cfDNA sample and the normal reference, ranging between -0.5 to 0.5. **D**, Tumor fraction of all baseline cfDNA of squamous (n = 152) and non-squamous (n = 73) NSCLC patients. **E**, CNV frequency in squamous baseline cfDNA of genes known to be associated with NSCLC.